Outcomes with dual RAAS inhibition with an ACE inhibitor and ARB vs standard therapy in patients on hemodialysis with CHF standard therapy in patients.

Slides:

Advertisements

Similar presentations

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.

Advertisements

McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.

CHARM Program: 3 Component trials comparing candesartan with placebo.

Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.

SOLVD (Studies of Left Ventricular Dysfunction)

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

First time a CETP inhibitor shows reduction of serious CV events

Prior Trials of RAAS Inhibitors

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Global Projections for Diabetes:

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Combining ACEI and ARB Therapy: The Next Step?

Adjusted relative mortality risk

Mean BP from initial visit to four years

Outcomes with trisodium citrate 30% vs heparin as catheter-locking solution (all catheters) in patients on hemodialysis Variable TSC, n (%) Heparin, n.

The following slides highlight a report on presentations at a Hotline Session and a Satellite Symposium of the European Society of Cardiology 2003 Congress.

Emerging Mechanisms in Glucose Metabolism

Cost Effectiveness and Optimal Outcomes in HF

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

ALLHAT: What Outcomes Would Have Been Expected?

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

T2DM and CV Outcomes Trials: A Deep Dive!

Recent studies of ACE inhibition in renal disease

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Differential effects of quinapril and losartan on superoxide production in endothelial cells Content Points: The interaction of NO and superoxide (O2-)

End point Fenoldopam, n (%) Dopamine, n (%) p

CREATE: Baseline values

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Nat. Rev. Cardiol. doi: /nrcardio

Volume 80, Issue 9, Pages (November 2011)

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Patient characteristics: American vs Canadian transplant patients

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

2015 EASD In Review: CV Risk management in t2dm

Managing Blood Pressure

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Fish oil for prevention of sudden death in hemodialysis patients?

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond)

Lipids, the Heart, and the Kidney

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Presentation transcript:

Outcomes with dual RAAS inhibition with an ACE inhibitor and ARB vs standard therapy in patients on hemodialysis with CHF standard therapy in patients on hemodialysis with CHF End point ACE plus ARB Standard therapy p All-cause mortality (%) 58.3 73.1 <0.001 CV death (%) 39 49.3 CHF hospitalization (%) 37.7 68.4 <0.0001 Cice G et al.The XLII ERA/EDTA Congress; June 4-7, 2005; Istanbul, Turkey.

Reductions in proteinuria with enalapril, losartan, or the combination at 12 weeks in kidney-transplant patients End point Enalapril Losartan Enalapril plus losartan Decrease in proteinuria (%) 17.6 17.3 27.2 Tuncer MA et al. The XLII ERA/EDTA Congress; June 4-7, 2005; Istanbul, Turkey.